This website will be unavailable from Thursday, May 30, 2024 at 6:00 p.m. through Monday, June 3, 2024 at 7:00 a.m. due to data center maintenance.

 
 
  By: Oliverson H.B. No. 3922
 
 
 
A BILL TO BE ENTITLED
 
AN ACT
  relating to information provided by health care providers and
  hospitals to certain patients regarding pharmaceutical
  manufacturer patient assistance programs for insulin.
         BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
         SECTION 1.  Subchapter N, Chapter 531, Government Code, is
  amended by adding Section 531.509 to read as follows:
         Sec. 531.509.  INFORMATION ON PHARMACEUTICAL MANUFACTURER
  PATIENT ASSISTANCE PROGRAMS FOR INSULIN. (a) This section applies
  to health care providers and hospitals that receive uncompensated
  care pool payments from the commission, including:
               (1)  federally qualified health centers as defined by
  42 U.S.C. Section 1396d(l)(2)(B);
               (2)  rural health clinics as defined by 42 U.S.C.
  Section 1396d(l)(1); and
               (3)  physician group practices.
         (b)  A health care provider or hospital to which this section
  applies shall provide to patients who have diabetes and require
  insulin information regarding the availability of pharmaceutical
  manufacturer patient assistance programs, including copay cards,
  that may reduce the cost of insulin to the patients.
         (c)  The executive commissioner shall adopt rules to
  implement this section.
         SECTION 2.  If before implementing any provision of this Act
  a state agency determines that a waiver or authorization from a
  federal agency is necessary for implementation of that provision,
  the agency affected by the provision shall request the waiver or
  authorization and may delay implementing that provision until the
  waiver or authorization is granted.
         SECTION 3.  This Act takes effect September 1, 2021.